Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6642920 | PMC |
| http://dx.doi.org/10.3345/kjp.2019.00108 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effectiveness and safety of perampanel by concomitant antiseizure medications: Insights from the real-world PERMIT Extension study.
Epilepsy Behav
October 2025
Hospital Universitario y Politécnico La Fe, Member of the ERN EpiCARE, Valencia, Spain. Electronic address:
The PERMIT Extension study is the largest pooled analysis of perampanel (PER) clinical practice data to date. A post-hoc analysis of PERMIT Extension assessed the effectiveness and tolerability of PER with different concomitant antiseizure medication (ASM) regimens. Effectiveness was assessed by evaluating responder and seizure freedom rates at the last observation for each participant ('last visit'), and tolerability was assessed by evaluating adverse events.
View Article and Find Full Text PDFEffectiveness of perampanel as the only adjunctive anti-seizure medication in adults: Final results from the observational PERPRISE study in Germany.
Epilepsia Open
August 2025
Department of Neurology, University of Saarland, Homburg, Germany.
Objective: The PERPRISE study (Study 509; NCT04202159) was a prospective, observational, non-interventional study in a real-world setting in Germany. This study was conducted to evaluate the effectiveness of perampanel as the only adjunctive treatment for 12 months in patients aged ≥18 years with focal to bilateral tonic-clonic seizures (FBTCS) or generalized tonic-clonic seizures (GTCS) in clinical practice.
Methods: Adult patients with FBTCS or GTCS received perampanel as an adjunctive therapy to anti-seizure medication (ASM) monotherapy (add-on therapy) or as a substitute for one ASM in dual therapy (substitution therapy) per the approved indication.
Treatment of epilepsy using newer antiseizure medications: A retrospective cohort study of prescription patterns in Sweden 2013-2022.
Epilepsia
August 2025
Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Objective: This study aimed to analyze the choice of newly introduced antiseizure medications (ASMs; brivaracetam, cannabidiol, cenobamate, fenfluramine, and perampanel) by age and sex, and the use of these ASMs in relation to regulatory approval.
Methods: Patients were identified with dispensation of any ASM subsequent to at least one health care contact due to epilepsy (International Classification of Diseases, 10th Revision: G40) during 2000-2022. Incidence rate ratios (IRRs) for starting a newly introduced ASM, retention rates, number of ASM treatments preceding the first dispensation of a new ASM and concurrent ASM treatments at first dispensed new ASM, and share of patients using new ASMs as adjunctive treatment were calculated.
Effectiveness and safety of perampanel in Lennox-Gastaut syndrome: a GRADE-assessed systematic review and meta-analysis.
Naunyn Schmiedebergs Arch Pharmacol
July 2025
Faculty of Medicine, Al-Azhar University, Damietta, Egypt.
This systematic review and meta-analysis aims to evaluate the effectiveness and safety of perampanel (PER) as adjunctive therapy in patients with Lennox-Gastaut Syndrome (LGS), focusing on seizure outcomes and adverse events (AEs). A comprehensive literature search was conducted across PubMed, Scopus, Web of Science, and Cochrane CENTRAL up to June 2025. Clinical trials and observational studies assessing PER in LGS patients were included.
View Article and Find Full Text PDFReal-world utilization of Cenobamate as adjunct therapy in office-based neurology: practical tips and insights for titration.
Front Neurol
June 2025
Zentrum für Neurologie in Berlin-Charlottenburg, Berlin, Germany.
Introduction: Epilepsy poses significant management challenges, particularly in patients with refractory epilepsy where conventional antiseizure medications (ASMs) are ineffective. Cenobamate (CNB), a recently approved third-generation ASM, has shown unprecedented efficacy as an adjunctive therapy in clinic-based practice. However, to date, its use by office-based neurologists in Germany remains relatively limited.
View Article and Find Full Text PDF